A Randomized, Double-Blind, Placebo Controlled, Two-Way Cross-Over Study of Analgesic Efficacy of Bupivacaine Transdermal Therapeutic System in Patients With Post-Herpetic Neuralgia
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2009
At a glance
- Drugs Bupivacaine (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors DURECT Corporation
- 03 Feb 2009 Status changed from recruiting to completed.
- 20 Dec 2007 Detailed results are anticipated to be presented at APS in May 2008.
- 18 Dec 2007 Interim results reported in a DURECT Corporation media release.